ID   MDC1_MOUSE              Reviewed;        1707 AA.
AC   Q5PSV9; Q52KG1; Q5U4D3; Q6ZQH7;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   04-JAN-2005, sequence version 1.
DT   07-APR-2021, entry version 131.
DE   RecName: Full=Mediator of DNA damage checkpoint protein 1;
GN   Name=Mdc1; Synonyms=Kiaa0170;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], INTERACTION WITH H2AX AND NBN, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15611643; DOI=10.4161/cc.4.1.1354;
RA   Lee A.C., Fernandez-Capetillo O., Pisupati V., Jackson S.P.,
RA   Nussenzweig A.;
RT   "Specific association of mouse MDC1/NFBD1 with NBS1 at sites of DNA-
RT   damage.";
RL   Cell Cycle 4:177-182(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 693-1707.
RC   TISSUE=Embryonic tail;
RX   PubMed=14621295; DOI=10.1093/dnares/10.4.167;
RA   Okazaki N., Kikuno R., Ohara R., Inamoto S., Koseki H., Hiraoka S.,
RA   Saga Y., Nagase T., Ohara O., Koga H.;
RT   "Prediction of the coding sequences of mouse homologues of KIAA gene: III.
RT   The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs
RT   identified by screening of terminal sequences of cDNA clones randomly
RT   sampled from size-fractionated libraries.";
RL   DNA Res. 10:167-180(2003).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168; SER-438; SER-442 AND
RP   THR-444, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=19131326; DOI=10.1074/mcp.m800451-mcp200;
RA   Sweet S.M., Bailey C.M., Cunningham D.L., Heath J.K., Cooper H.J.;
RT   "Large scale localization of protein phosphorylation by use of electron
RT   capture dissociation mass spectrometry.";
RL   Mol. Cell. Proteomics 8:904-912(2009).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168; SER-438; SER-442;
RP   THR-444; SER-461; THR-470; SER-492; SER-493; SER-591; SER-593; SER-595;
RP   THR-1056; SER-1104; SER-1126; SER-1128; THR-1132; THR-1297; THR-1298;
RP   SER-1435; SER-1436; SER-1439; SER-1443 AND THR-1480, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Kidney, Liver, Lung, Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=23039116; DOI=10.1111/gtc.12005;
RA   Kogo H., Tsutsumi M., Inagaki H., Ohye T., Kiyonari H., Kurahashi H.;
RT   "HORMAD2 is essential for synapsis surveillance during meiotic prophase via
RT   the recruitment of ATR activity.";
RL   Genes Cells 17:897-912(2012).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1496, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=23806337; DOI=10.1016/j.molcel.2013.06.001;
RA   Park J., Chen Y., Tishkoff D.X., Peng C., Tan M., Dai L., Xie Z., Zhang Y.,
RA   Zwaans B.M., Skinner M.E., Lombard D.B., Zhao Y.;
RT   "SIRT5-mediated lysine desuccinylation impacts diverse metabolic
RT   pathways.";
RL   Mol. Cell 50:919-930(2013).
CC   -!- FUNCTION: Required for checkpoint mediated cell cycle arrest in
CC       response to DNA damage within both the S phase and G2/M phases of the
CC       cell cycle. May serve as a scaffold for the recruitment of DNA repair
CC       and signal transduction proteins to discrete foci of DNA damage marked
CC       by 'Ser-139' phosphorylation of histone H2AX. Also required for
CC       downstream events subsequent to the recruitment of these proteins.
CC       These include phosphorylation and activation of the ATM, CHEK1 and
CC       CHEK2 kinases, and stabilization of TP53 and apoptosis. ATM and CHEK2
CC       may also be activated independently by a parallel pathway mediated by
CC       TP53BP1 (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer. Interacts with several proteins involved in the DNA
CC       damage response, although not all these interactions may be direct.
CC       Interacts with CHEK2, which requires ATM-mediated phosphorylation
CC       within the FHA domain of CHEK2. Interacts constitutively with the
CC       BRCA1-BARD1 complex, SMC1A and TP53BP1. Interacts with ATM and FANCD2,
CC       and these interactions are reduced upon DNA damage. Also interacts with
CC       the PRKDC complex, composed of XRCC6/KU70, XRCC5/KU80 and PRKDC/XRCC7.
CC       This interaction may be required for PRKDC autophosphorylation, which
CC       is essential for DNA double strand break (DSB) repair. When
CC       phosphorylated by ATM, interacts with RNF8 (via FHA domain). Interacts
CC       with CEP164. When phosphorylated, interacts with APTX (via FHA-like
CC       domain) (By similarity). Interacts with H2AX, which requires
CC       phosphorylation of H2AX. Interacts with the MRN complex, composed of
CC       MRE11, RAD50, and NBN. {ECO:0000250, ECO:0000269|PubMed:15611643}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome. Note=Associated with
CC       chromatin. Relocalizes to discrete nuclear foci following DNA damage,
CC       this requires phosphorylation of H2AX. Colocalizes with APTX at sites
CC       of DNA double-strand breaks (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: Tandemly repeated BRCT domains are characteristic of proteins
CC       involved in DNA damage signaling. In MDC1, these repeats are required
CC       for localization to chromatin which flanks sites of DNA damage marked
CC       by 'Ser-139' phosphorylation of H2AX (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated upon exposure to ionizing radiation (IR),
CC       ultraviolet radiation (UV), and hydroxyurea (HU). Phosphorylation in
CC       response to IR requires ATM, NBN, and possibly CHEK2. Also
CC       phosphorylated during the G2/M phase of the cell cycle and during
CC       activation of the mitotic spindle checkpoint. Phosphorylation at Thr-4
CC       by ATM stabilizes and enhances homodimerization via the FHA domain (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Sumoylation at Lys-1461 by PIAS4 following DNA damage promotes
CC       ubiquitin-mediated degradation. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by RNF4, leading to proteasomal degradation;
CC       undergoes 'Lys-48'-linked polyubiquitination. {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY826432; AAV85449.1; -; Genomic_DNA.
DR   EMBL; BC085140; AAH85140.1; -; mRNA.
DR   EMBL; BC094363; AAH94363.1; -; mRNA.
DR   EMBL; AK129074; BAC97884.1; -; mRNA.
DR   RefSeq; NP_001010833.2; NM_001010833.2.
DR   PDB; 3VA1; X-ray; 1.74 A; A/B=29-139.
DR   PDB; 3VA4; X-ray; 1.54 A; A/B=29-139.
DR   PDBsum; 3VA1; -.
DR   PDBsum; 3VA4; -.
DR   SMR; Q5PSV9; -.
DR   BioGRID; 232163; 6.
DR   STRING; 10090.ENSMUSP00000080949; -.
DR   iPTMnet; Q5PSV9; -.
DR   PhosphoSitePlus; Q5PSV9; -.
DR   EPD; Q5PSV9; -.
DR   jPOST; Q5PSV9; -.
DR   MaxQB; Q5PSV9; -.
DR   PaxDb; Q5PSV9; -.
DR   PeptideAtlas; Q5PSV9; -.
DR   PRIDE; Q5PSV9; -.
DR   ProteomicsDB; 293442; -.
DR   GeneID; 240087; -.
DR   KEGG; mmu:240087; -.
DR   CTD; 9656; -.
DR   MGI; MGI:3525201; Mdc1.
DR   eggNOG; KOG2043; Eukaryota.
DR   InParanoid; Q5PSV9; -.
DR   OrthoDB; 670424at2759; -.
DR   PhylomeDB; Q5PSV9; -.
DR   Reactome; R-MMU-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-MMU-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-MMU-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-MMU-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-MMU-69473; G2/M DNA damage checkpoint.
DR   BioGRID-ORCS; 240087; 8 hits in 52 CRISPR screens.
DR   ChiTaRS; Mdc1; mouse.
DR   PRO; PR:Q5PSV9; -.
DR   Proteomes; UP000000589; Unplaced.
DR   RNAct; Q5PSV9; protein.
DR   GO; GO:0005694; C:chromosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; ISO:MGI.
DR   GO; GO:0016604; C:nuclear body; ISO:MGI.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; ISO:MGI.
DR   GO; GO:0070975; F:FHA domain binding; ISO:MGI.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0008022; F:protein C-terminus binding; ISO:MGI.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   CDD; cd00060; FHA; 1.
DR   Gene3D; 3.40.50.10190; -; 2.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR000253; FHA_dom.
DR   InterPro; IPR008984; SMAD_FHA_dom_sf.
DR   Pfam; PF00498; FHA; 1.
DR   Pfam; PF16770; RTT107_BRCT_5; 1.
DR   SMART; SM00292; BRCT; 2.
DR   SMART; SM00240; FHA; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   SUPFAM; SSF52113; SSF52113; 1.
DR   PROSITE; PS50172; BRCT; 1.
DR   PROSITE; PS50006; FHA_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell cycle; Chromosome; Coiled coil; DNA damage;
KW   DNA repair; Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; Ubl conjugation.
FT   CHAIN           1..1707
FT                   /note="Mediator of DNA damage checkpoint protein 1"
FT                   /id="PRO_0000096318"
FT   DOMAIN          54..105
FT                   /note="FHA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00086"
FT   DOMAIN          1510..1588
FT                   /note="BRCT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   DOMAIN          1609..1700
FT                   /note="BRCT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   REGION          1..150
FT                   /note="Interaction with CHEK2"
FT                   /evidence="ECO:0000250"
FT   REGION          2..222
FT                   /note="Interaction with the MRN complex"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        995..1394
FT                   /note="Pro-rich"
FT   MOD_RES         4
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         146
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         168
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:19131326, ECO:0007744|PubMed:19144319,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         176
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5U2M8"
FT   MOD_RES         298
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         300
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         313
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         315
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         360
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         362
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         385
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         387
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         415
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5U2M8"
FT   MOD_RES         425
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5U2M8"
FT   MOD_RES         438
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         442
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         444
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:21183079"
FT   MOD_RES         461
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         470
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         492
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         493
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         591
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         593
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         595
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         735
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         750
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         769
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         885
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         929
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         962
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q5U2M8"
FT   MOD_RES         991
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         1056
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1104
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1126
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1128
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1132
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1173
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         1234
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         1297
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1298
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1327
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         1352
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         1359
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         1375
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   MOD_RES         1435
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1436
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1439
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1443
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1480
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         1496
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:23806337"
FT   CROSSLNK        1418
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   CROSSLNK        1461
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   CROSSLNK        1461
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q14676"
FT   CONFLICT        396
FT                   /note="E -> EE (in Ref. 2; AAH94363)"
FT                   /evidence="ECO:0000305"
FT   STRAND          31..36
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          45..49
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          51..59
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          62..65
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          76..80
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          88..91
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          98..100
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   TURN            101..104
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          105..107
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          120..123
FT                   /evidence="ECO:0007744|PDB:3VA4"
FT   STRAND          126..132
FT                   /evidence="ECO:0007744|PDB:3VA4"
SQ   SEQUENCE   1707 AA;  184670 MW;  F6ECCD30BBED265D CRC64;
     MESTQVIDWD AEEEEETELS SGSLGYSVEP IGQLRLFSGT HGPERDFPLY LGKNVVGRSP
     DCSVALPFPS ISKQHAVIEI SAWNKAPILQ DCGSLNGTQI VKPPRVLPPG VSHRLRDQEL
     ILFADFPCQY HRLDVPPPLV PRSLLTIEKT PRIRIESQNS RVLLAADSEE EGDFPSGRCV
     ANGQRNTASP SATVVPESDE EVSSPAPSVP GPSSPFGLGS DTDEEQGQQP GVEESSLADS
     SGAAGEAEQP EANGTTAGIQ AQPTEHKLKD TKVKKEAGRA GVSDGSVLER SPTLGEDSDT
     EVDEDHKPGF ADSETDVEEE RIPVTPPVAP VKKNQVLLAV GIGDPEAPGV AHLQDCLAGS
     GTDVEDKTAL DVPLERNHTP MVINSDTDEE EEEEEEVSAA LTLAHLKERG IGLWSRDPGA
     EEVKSQPQVL VEQSQSASGR DSDTDVEEES SGRKREIIPD SPMDVDEALT VTQPESQPPR
     RPNDADEYMD MSSPGSHLVV NQASFAVVGK TRAQVEEEVP GPSVILGEKH QVPLEGAQPP
     EEAWETAVQE GSSSPEAAAS VRPSQQPVAE DAGTECATAV SEQESTLEVR SQSGSPAAPV
     EQVVIHTDTS GDPTLPQREG AQTPTGRERE AHVGRTKSAK ECCDAEPEDL CLPATQCFVE
     GESQHPEAVQ SLENEPTQLF PCTLPQEPGP SHLSLQTPGA DTLDVPWEVL ATQPFCLREQ
     SETSELHEAH GSQPSLPREP PGHQHLVHTS PVHTELLRIE GREIQTVEKA MGIPKEMADR
     MTPEREPLER EIRGRTENSE RDVIGEELIQ GTKDREPKKV LARDSQRKEA DKDLEGNRES
     LEVEIEMSKD SQKRERKVEK PEPKREWEPA DLEVTPDRGV TEEGSHDQKG QIASLTLKPG
     VGVKDLEGLA SAPIITGSQA DGGKGDPLSP GRQQRGRLSC QTTPAGKASR GDPEPPDHCL
     FSSVPEASTQ SLLTSQSQKQ STPQPLFSTS SSEIPLPESL HTKPNVRPRR SSRMTPSPHS
     SAALKPNTTC PTNQPAASRP TSRPTRGRAN RSSTRTPELI VPVDPELQPS TSTEQPVIPK
     LTSQVTEGRV QMPEPLLTGP EIQSPTSTEQ SVTPDRKPRA TRGRPSKSPN KTPEPLISTG
     PELQPPTSIE QPVIPKPTSR VTRGRPRKSS VRTPESVVST GPELQPLTSI EQPVIPEPRA
     TRGRPSKSSI KTPESVVPTG PELQPLTSAK QPVTPNLTSR ASRGRSSKSI RTPEPVVQTG
     PEFHPSTSTE QPDTREPSSQ ARTRRSAVKT PEASVPTTPE LQPFTSKKQP APKPTALVTQ
     GRTYKPSTED CESVGPVAPD FEPSTSTDHL VTPKVTDQSL TLQSSPLSAS PVSSTPDLKP
     PVPIAQPVTP EPIPQANHQR KRRAAGKQGS RTVPLGHKSY SALSEPEPQS SASQSSGASE
     ADSPRQKRPR RQASQKTVVI KEEPVETEVK EEPQETAIPT PEKRKRDHAE EVTQGKPTRS
     RRTKPNQETA PKVLFTGVMD SRGERAVLAL GGSLASSVNE ASHLVTDRIR RTVKFLCALG
     KGIPILSLNW LYQSRKAGCF LPPDDYLVTD PEQEKNFSFS LRDSLCRARE RRLLEDYEIH
     VTPGVQPPPP QMGEIISCCG GTFLPSMPHS YKLHRVIITC TEDLPRCAIP SRLGLPLLSP
     EFLLTGVLKQ EATPEAFVLS NLEMSST
//
